TRVI — Trevi Therapeutics, Inc.

Trevi Therapeutics (TRVI) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: Reported a net loss of $11.8 million for Q3 2025, an improvement from a net loss of $13.2 million in Q3 2024.
• R&D Expenses: Decreased to $10.1 million from $11.2 million year-over-year, attributed to reduced clinical trial activity.
• Cash Position: Cash and investments totaled approximately $195 million, providing a runway into 2028, enabling funding for upcoming clinical trials.

2. Strategic Updates and Business Highlights

• Clinical Trials: Positive data from the CORAL trial (chronic cough in IPF) and RIVER trial (refractory chronic cough) were presented at the CHEST conference, generating significant interest.
• Phase I Studies: Completed drug-drug interaction studies with no significant pharmacokinetic changes noted, allowing progression to Phase III planning.
• Upcoming Trials: Preparing for Phase III trials in chronic cough for both IPF and non-IPF interstitial lung diseases (ILD) and a Phase 2b trial for refractory chronic cough, with initiation expected in the first half of 2026.
• Market Opportunity: The non-IPF ILD population is estimated at 228,000 patients, potentially doubling the market opportunity for chronic cough treatments.

3. Forward Guidance and Outlook

• Phase III Initiation: Anticipated to request an end-of-Phase II meeting with the FDA in Q4 2025 to discuss study design and parameters for chronic cough in IPF and non-IPF ILD.
• Regulatory Strategy: Plans to apply for orphan drug designation for IPF cough post-end of Phase II meeting.
• Market Positioning: The company aims to enhance awareness of chronic cough as a significant health issue, targeting key prescribers as they prepare for market entry.

4. Bad News, Challenges, or Points of Concern

• Regulatory Hurdles: The need for additional drug-drug interaction studies may delay timelines and increase costs.
• Competitive Landscape: The evolving treatment landscape for IPF and chronic cough could impact market positioning, particularly with new entrants like United Therapeutics.
• Safety Studies: The FDA's request for a respiratory safety study raised concerns about potential long-term effects, despite previous data showing no significant safety signals.

5. Notable Q&A Insights

• Inclusion Criteria for Trials: The company plans to keep eligibility criteria broad for future trials to reflect real-world patient populations, allowing for a diverse range of comorbidities.
• Market Strategy: Feedback from the CHEST conference indicated strong interest from pulmonologists, and the company is focusing on raising awareness of chronic cough.
• Phase III Design: The Phase III program will allow background antifibrotics, with a focus on a 54 mg BID dosing regimen based on previous trial learnings.
• Regulatory Communication: The FDA has been responsive, and the company is optimistic about obtaining clear guidance in upcoming meetings.

Overall, Trevi Therapeutics is positioned to advance its clinical programs with a solid financial foundation, although it faces regulatory and competitive challenges as it seeks to establish its therapies in the market.